Department of Epidemiology & Cancer Control, St. Jude Children's Research Hospital, 262 Danny Thomas Pl, MS-735, Memphis, TN 38105, USA.
J Natl Cancer Inst. 2013 Apr 3;105(7):504-8. doi: 10.1093/jnci/djt014. Epub 2013 Mar 20.
Adult survivors of childhood cancer are known to be at increased risk of subsequent malignancy, but only limited data exist describing the incidence and risk factors for secondary renal carcinoma. Among 14 358 5-year survivors diagnosed between 1970 and 1986, we estimated standardized incidence ratios (SIRs) for subsequent renal carcinoma and identified associations with primary cancer therapy using Poisson regression. Twenty-six survivors were diagnosed with renal carcinoma (median = 22.6 years from diagnosis; range = 6.3-35.7 years), reflecting a statistically significant excess (SIR = 8.0, 95% confidence interval [CI] = 5.2 to 11.7) compared with the general population. Highest risk was observed among neuroblastoma survivors (SIR = 85.8, 95% CI = 38.4 to 175.2) and, in multivariable analyses, with renal-directed radiotherapy of 5 Gy or greater (relative risk [RR] = 3.8, 95% CI = 1.6 to 9.3) and platinum-based chemotherapy (RR = 3.5, 95% CI = 1.0 to 11.2). To our knowledge, this is the first report of an association between cisplatin and subsequent renal carcinoma among survivors of childhood cancer.
已知儿童癌症的成年幸存者患随后发生的恶性肿瘤的风险增加,但仅有有限的数据描述继发性肾癌的发病率和危险因素。在 1970 年至 1986 年间诊断出的 14358 名 5 年幸存者中,我们使用泊松回归估计了随后发生的肾癌的标准化发病比(SIR),并确定了与原发性癌症治疗的关联。有 26 名幸存者被诊断出患有肾癌(中位数为诊断后 22.6 年;范围为 6.3-35.7 年),与普通人群相比,这反映出统计学上显著的超额(SIR = 8.0,95%置信区间 [CI] = 5.2 至 11.7)。神经母细胞瘤幸存者的风险最高(SIR = 85.8,95% CI = 38.4 至 175.2),并且在多变量分析中,5 Gy 或更大剂量的肾靶向放疗(相对风险 [RR] = 3.8,95% CI = 1.6 至 9.3)和铂类化疗(RR = 3.5,95% CI = 1.0 至 11.2)。据我们所知,这是首例关于顺铂与儿童癌症幸存者随后发生肾癌之间关联的报告。